Alnylam-discovered Livsayis wins FDA approval for generalized myasthenia gravis
REGN•The FDA approved Livsayis for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, triggering a $25 million payment to Alnylam and eligibility for tiered royalties of up to 15% of global net sales.
1. FDA approval
The FDA approved Alnylam-discovered Livsayis (cemdisiran) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The approval triggers a $25 million payment to Alnylam, which is also eligible for tiered, double-digit royalties of up to 15% of global net sales.
2. Development and dosing
Regeneron assumed sole responsibility for the drug’s development, manufacturing and commercialization in 2024 after Alnylam advanced it into Phase 2. Livsayis silences messenger RNA encoding complement component 5, and patients receive subcutaneous doses four times yearly.




